David Fajgenbaum

occupation: researcher, international forum participant

David C. Fajgenbaum (born March 29, 1985) is an American immunologist and author who is currently an assistant professor at the Perelman School of Medicine of the University of Pennsylvania. He is most well known for his research into Castleman disease. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 23

Date

Title

Authors

2020-05-11

Treatments administered to the first 9,152 reported cases of COVID19: a systematic review

David Fajgenbaum
2020-05-27

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

David Fajgenbaum
2020-09-07

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

David Fajgenbaum, Raymond Siu-Ming Wong, Simone Ferrero, Angela Dispenzieri, Pier Luigi Zinzani, Frits van Rhee, Alexander Fosså
2020-12-01

Cytokine Storm

David Fajgenbaum, Carl H. June
2019-02-13

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

David Fajgenbaum, Jian Li
2019-08-13

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease

David Fajgenbaum, Daniel J Arenas, Katie Stone, Frits van Rhee, Michael R. Betts
2019-06-26

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease

Christopher S Nabel, David Fajgenbaum, Alexander Fosså, Katie Stone, Frits van Rhee
2018-02-01

Castleman Disease Pathogenesis

David Fajgenbaum
2018-09-04

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Frits van Rhee, Megan S Lim, Kojo Elenitoba-Johnson, Pier Luigi Zinzani, Simone Ferrero, Louis Terriou, Raymond Siu-Ming Wong, Corey Casper, David Fajgenbaum, Alexander Fosså, Elaine Jaffe, Angela Dispenzieri, Razelle Kurzrock, Katie Stone, Thomas S Uldrick, Amy Chadburn, Mary Jo Lechowicz
2018-11-01

A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease

David Fajgenbaum, David Martín-García, Minji Byun
2018-05-07

Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease

David Fajgenbaum, Jian Li
2018-11-29

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

David Fajgenbaum
2018-05-16

Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease

David Fajgenbaum, Katie Stone, Frits van Rhee
2018-09-11

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data

David Fajgenbaum, Frits van Rhee
2017-01-13

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease

Alexander Fosså, Frits van Rhee, Razelle Kurzrock, Amy Y Liu, David Fajgenbaum, Angela Dispenzieri, Elaine Jaffe
2017-01-26

TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease

David Fajgenbaum
2017-01-18

Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease

David Fajgenbaum, Jorge Eduardo Cortes, Jun Zhang, Robert Z Orlowski, Sattva S Neelapu, L Jeffrey Medeiros, Ken H Young
2017-09-22

TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature

Yves Chalandon, Louis Terriou, David Launay, David Fajgenbaum, Yannick D Muller, Jörg D Seebach
2017-11-16

The full spectrum of Castleman disease: 273 patients studied over 20 years.

Eric Oksenhendler, David Fajgenbaum, Marion Malphettes
2016-02-01

Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease

David Fajgenbaum, Eisei Kondo, Hiroshi Moro
2016-11-16

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

Fatemeh Behnia, David Fajgenbaum
2016-03-17

The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research.

David Fajgenbaum
2015-12-01

Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research

David Fajgenbaum

Human - wd:Q52983783

Welcome to Inventaire

the library of your friends and communities

learn more